CA2286909A1 - 5,7-disubstituted 4-aminopyrido¬2,3-d|pyrimidine compounds and their use as adenosine kinase inhibitors - Google Patents

5,7-disubstituted 4-aminopyrido¬2,3-d|pyrimidine compounds and their use as adenosine kinase inhibitors Download PDF

Info

Publication number
CA2286909A1
CA2286909A1 CA002286909A CA2286909A CA2286909A1 CA 2286909 A1 CA2286909 A1 CA 2286909A1 CA 002286909 A CA002286909 A CA 002286909A CA 2286909 A CA2286909 A CA 2286909A CA 2286909 A1 CA2286909 A1 CA 2286909A1
Authority
CA
Canada
Prior art keywords
amino
pyrido
pyrimidine
bromophenyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002286909A
Other languages
English (en)
French (fr)
Inventor
Shripad S. Bhagwat
Anne Laure Grillot
Chih-Hung Lee
Marlon D. Cowart
Jeffrey Mckie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2286909A1 publication Critical patent/CA2286909A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002286909A 1997-04-16 1998-04-14 5,7-disubstituted 4-aminopyrido¬2,3-d|pyrimidine compounds and their use as adenosine kinase inhibitors Abandoned CA2286909A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83821697A 1997-04-16 1997-04-16
US08/838,216 1997-04-16
PCT/US1998/007207 WO1998046605A1 (en) 1997-04-16 1998-04-14 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their use as adenosine kinase inhibitors

Publications (1)

Publication Number Publication Date
CA2286909A1 true CA2286909A1 (en) 1998-10-22

Family

ID=25276561

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002286909A Abandoned CA2286909A1 (en) 1997-04-16 1998-04-14 5,7-disubstituted 4-aminopyrido¬2,3-d|pyrimidine compounds and their use as adenosine kinase inhibitors

Country Status (18)

Country Link
EP (1) EP0989986A1 (xx)
JP (1) JP2001520655A (xx)
KR (1) KR20010006509A (xx)
CN (1) CN1252070A (xx)
AR (1) AR012436A1 (xx)
AU (1) AU7108398A (xx)
BG (1) BG103842A (xx)
BR (1) BR9809055A (xx)
CA (1) CA2286909A1 (xx)
CO (1) CO4940446A1 (xx)
HU (1) HUP0001434A3 (xx)
IL (1) IL131618A0 (xx)
NO (1) NO995036L (xx)
PL (1) PL336304A1 (xx)
SK (1) SK141799A3 (xx)
TR (1) TR199902455T2 (xx)
WO (1) WO1998046605A1 (xx)
ZA (1) ZA983177B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
IL156872A0 (en) 2001-02-12 2004-02-08 Hoffmann La Roche 6-substituted pyrido-pyrimidines
MXPA04006882A (es) 2002-01-17 2004-12-06 Neurogen Corp Analogos substituidos de quinazolin-4-ilamina como moduladores de receptores de capsaicina.
DE10335183A1 (de) * 2003-07-30 2005-02-24 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
ATE449097T1 (de) * 2005-07-21 2009-12-15 Hoffmann La Roche Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
AU2006330924B2 (en) * 2005-12-21 2012-03-15 Abbvie Inc. Anti-viral compounds
ES2395386T3 (es) 2005-12-21 2013-02-12 Abbott Laboratories Compuestos antivirales
EP2094276A4 (en) 2006-12-20 2011-01-05 Abbott Lab ANTIVIRAL COMPOUNDS
MX2010002258A (es) 2007-08-27 2010-04-22 Helicon Therapeutics Inc Compuestos terapeuticos de isoxazol.
EP2559693B1 (en) 2007-08-31 2014-11-26 Eisai R&D Management Co., Ltd. Polycyclic compound
DE102007061764A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung
WO2010098487A1 (en) * 2009-02-26 2010-09-02 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
WO2014055595A1 (en) 2012-10-05 2014-04-10 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitiors related applications
KR102514814B1 (ko) 2016-03-31 2023-03-27 온크터널 테라퓨틱스, 인코포레이티드. 인돌린 유사체 및 이의 용도
CN110256420B (zh) * 2019-05-07 2020-04-28 江西中医药大学 四氢吡啶并嘧啶衍生物及其制备方法和用途
CN110283171A (zh) * 2019-07-17 2019-09-27 鼎泰(南京)临床医学研究有限公司 一类含有吡啶并嘧啶-4-胺类结构的化合物、药物组合物以及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324731A (en) * 1989-02-14 1994-06-28 Amira, Inc. Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds

Also Published As

Publication number Publication date
JP2001520655A (ja) 2001-10-30
HUP0001434A2 (hu) 2000-10-28
NO995036D0 (no) 1999-10-15
WO1998046605A1 (en) 1998-10-22
CO4940446A1 (es) 2000-07-24
BG103842A (en) 2000-06-30
ZA983177B (en) 1999-01-22
EP0989986A1 (en) 2000-04-05
AU7108398A (en) 1998-11-11
TR199902455T2 (xx) 2000-01-21
CN1252070A (zh) 2000-05-03
IL131618A0 (en) 2001-01-28
AR012436A1 (es) 2000-10-18
SK141799A3 (en) 2000-08-14
PL336304A1 (en) 2000-06-19
BR9809055A (pt) 2000-08-08
NO995036L (no) 1999-10-15
KR20010006509A (ko) 2001-01-26
HUP0001434A3 (en) 2001-01-29

Similar Documents

Publication Publication Date Title
JP6248123B2 (ja) 塩誘導性キナーゼ２（ＳＩＫ２）阻害剤としての置換された１Ｈ−ピロロ［２，３−ｂ］ピリジン及び１Ｈ−ピラゾロ［３，４−ｂ］ピリジン誘導体
WO2000023444A1 (en) 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
KR102460389B1 (ko) Mnk 억제제 및 그와 관련된 방법
AU2010336386B2 (en) Aminopyrimidine kinase inhibitors
JP2018131449A (ja) ホスファチジルイノシトール３−キナーゼのイソインドリノンインヒビター
CA2286909A1 (en) 5,7-disubstituted 4-aminopyrido¬2,3-d|pyrimidine compounds and their use as adenosine kinase inhibitors
JP2021519783A (ja) Ｍａｔ２ａの複素二環式阻害剤、およびがんの治療のための使用方法
HU210814A9 (en) Pyrido pyridazinone and pyridazinthione compounds
EP2001884A1 (en) Deazapurines useful as inhibitors of janus kinases
SK16972002A3 (sk) Beta-karbolínové deriváty použiteľné ako inhibítory fosfodiesterázy
TW202130641A (zh) 可用作shp2抑制劑的含氮雜原子的六元並五元芳環衍生物
CN116406271A (zh) 双环类化合物
CN111484494A (zh) 抑制mnk1和mnk2的多环化合物
CN116782903A (zh) 取代的吡啶酮化合物及应用
CZ44093A3 (en) L-glutamic acid derivative, process for preparing thereof and pharmaceutical preparation in which said derivative is comprised
AU7098198A (en) 6,7-disubstituted-4-aminopyrido(2,3-d)pyrimidine compounds
US6030969A (en) 5,6,7-trisubstituted-4-aminopyrido[2,3-D] pyrimidine compounds
WO1998046604A1 (en) 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds
CZ339399A3 (cs) 5,7-Disubstituované 4-aminopyrido[2.3- D]pyrimidinové sloučeniny a jejich použití jako inhibitorů adenosin kinasy
KR20230171440A (ko) 약학적 화합물
MXPA99009512A (en) 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds
CZ350899A3 (cs) 5,6,7-trisubstituované-4-aminopyrido-[2,3- D]pyrimidinové sloučeniny
CZ360199A3 (cs) Sloučeniny 6,7-disubstituovaného-4- aminopyrido [2,3-dJ pyrimidinu

Legal Events

Date Code Title Description
FZDE Discontinued